Actively Recruiting

Phase 4
Age: 0 - 9Years
All Genders
NCT06601712

Post-discharge Malaria Chemoprevention Implementation Trial in Benin

Led by Institut de Recherche Clinique du Benin · Updated on 2025-07-24

648

Participants Needed

2

Research Sites

78 weeks

Total Duration

On this page

Sponsors

I

Institut de Recherche Clinique du Benin

Lead Sponsor

L

Liverpool School of Tropical Medicine

Collaborating Sponsor

AI-Summary

What this Trial Is About

The proposed research aims to conduct implementation trials in Benin, co-designed with national stakeholders, to evaluate different delivery strategies for optimizing health system delivery of post-discharge malaria chemoprevention (PDMC) drugs and adherence to PDMC. This chemoprevention strategy is effective in reducing hospital readmissions and deaths after discharge. However, there is no clear delivery platform for PDMC, and adherence to the 3-day dosing regimen, provided monthly three times after discharge, is a potential limitation. The current trial will provide evidence-based data on acceptability, feasibility, and cost-effectiveness to aid decision-makers. The evidence generated will be used to support the effective implementation and scale-up of PDMC in high malaria-endemic areas such as Benin.

CONDITIONS

Official Title

Post-discharge Malaria Chemoprevention Implementation Trial in Benin

Who Can Participate

Age: 0 - 9Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Aged below 10 years of both sexes
  • Hospitalised with severe anaemia or severe malaria defined by haemoglobin below 5.0 g/dl or PCV below 15%, or requirement for blood transfusion, or confirmed malaria infection requiring parenteral artesunate
  • Clinically stable and able to take oral medication
  • Post-transfusion haemoglobin below 5 g/dL
Not Eligible

You will not qualify if you...

  • Recognised specific other causes of severe anaemia such as trauma, haematological malignancy, or known bleeding disorders like haemophilia
  • Sickle cell anaemia or sickle cell disease
  • Body weight below 5 kg
  • Non-resident in the study area
  • Previous participation in the study
  • Need for prohibited medication or scheduled surgery during the 6-month study period

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 2 locations

1

Goho Departmental Hospital Centre

Abomey, Benin

Not Yet Recruiting

2

Centre Hospitalier Universitaire de la Mere et de l'Enfant Lagune (CHU-MEL)

Cotonou, Benin

Actively Recruiting

Loading map...

Research Team

M

Manfred Accrombessi, MD, PhD

CONTACT

A

Achille Massougbodji, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here